Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

Abstract Trial design We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment with the first-in-class co-stimulatory blocker abatacept for p...

Full description

Bibliographic Details
Main Authors: Mariam Al-Laith, Marianna Jasenecova, Sonya Abraham, Aisla Bosworth, Ian N. Bruce, Christopher D. Buckley, Coziana Ciurtin, Maria-Antonietta D’Agostino, Paul Emery, Hill Gaston, John D. Isaacs, Andrew Filer, Benjamin A. Fisher, Thomas W. J. Huizinga, Pauline Ho, Clare Jacklin, Heidi Lempp, Iain B. McInnes, Arthur G. Pratt, Andrew Östor, Karim Raza, Peter C. Taylor, Dirkjan van Schaardenburg, Dharshene Shivapatham, Alison J. Wright, Joana C. Vasconcelos, Joanna Kelly, Caroline Murphy, A. Toby Prevost, Andrew P. Cope
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Trials
Subjects:
Rheumatoid arthritis
At risk
Pre-clinical phase
Intervention
Abatacept
Double-blind
Online Access:http://link.springer.com/article/10.1186/s13063-019-3403-7

Internet

http://link.springer.com/article/10.1186/s13063-019-3403-7

Similar Items